IPP Bureau

CHMP recommends EU approval of Roche’s new combination treatment for large B-cell lymphoma
CHMP recommends EU approval of Roche’s new combination treatment for large B-cell lymphoma

By IPP Bureau - March 25, 2022

Recommendation is based on pivotal data from the phase III POLARIX study

Japan approves BMS’ Breyanzi application for relapsed large B-cell lymphoma
Japan approves BMS’ Breyanzi application for relapsed large B-cell lymphoma

By IPP Bureau - March 25, 2022

This is the first CAR T cell therapy application filed for the second-line treatment of R/R LBCL in Japan

SRL Diagnostics launches whole genome sequencing test for Tuberculosis
SRL Diagnostics launches whole genome sequencing test for Tuberculosis

By IPP Bureau - March 24, 2022

The test can overcome the time and cost limitations of traditional culture-based drug susceptibility testing as it can more rapidly detect all mutations known to be associated with drug resistance for any TB drug in one step

HaystackAnalytics sees alarming rise in TB cases
HaystackAnalytics sees alarming rise in TB cases

By IPP Bureau - March 24, 2022

A staggering 65% of the TB cases in India are in the 15-45 age group

LifeMine Therapeutics and GSK enter drug discovery and development alliance
LifeMine Therapeutics and GSK enter drug discovery and development alliance

By IPP Bureau - March 24, 2022

The collaboration will utilize Avatar-Rx, LifeMine’s proprietary genomically-enabled drug discovery platform to access evolutionarily derived lead small molecules

Johnson & Johnson India launches ‘Be The Change For TB’ initiative
Johnson & Johnson India launches ‘Be The Change For TB’ initiative

By IPP Bureau - March 24, 2022

#BeTheChangeForTB is a public awareness initiative under the Corporate TB Pledge and aims to create a cadre of Youth Changemakers who can act as catalysts of change to help eliminate TB from India

Lupin receives approval from USFDA for Sildenafil for Oral Suspension
Lupin receives approval from USFDA for Sildenafil for Oral Suspension

By IPP Bureau - March 24, 2022

The product will be manufactured at Lupin’s facility in Goa, India

USFDA approves Novartis Pluvicto to treat prostrate cancer
USFDA approves Novartis Pluvicto to treat prostrate cancer

By IPP Bureau - March 24, 2022

USFDA also approved complementary diagnostic imaging agent, Locametz, after radiolabeling with gallium-68 for the identification of PSMA-positive lesions

MedisimVR raises Rs 3.5 cr. in Pre-Series A round led by Inflection Point Ventures
MedisimVR raises Rs 3.5 cr. in Pre-Series A round led by Inflection Point Ventures

By IPP Bureau - March 24, 2022

MedisimVR is a VR based medical education platform for doctors, nurses & allied health professionals. It aims to make comprehensive Virtual Reality medical simulation more accessible and affordable

Carestream Health India launch Lux 35 detector
Carestream Health India launch Lux 35 detector

By IPP Bureau - March 24, 2022

The new glass-free detector has improved durability, is more reliable, and has an improved rugged design to sustain in a high workload environment

Kiran Mazumdar-Shaw elected as the Fellow of Royal Society of Edinburgh
Kiran Mazumdar-Shaw elected as the Fellow of Royal Society of Edinburgh

By IPP Bureau - March 24, 2022

Kiran will be joining RSE's current Fellowship of around 1,700 Fellows who are recognized as being some of the greatest thinkers, researchers and practitioners working in or with Scotland

Pfizer granted USFDA Breakthrough Therapy Designation for RSV vaccine candidate
Pfizer granted USFDA Breakthrough Therapy Designation for RSV vaccine candidate

By IPP Bureau - March 24, 2022

The FDA decision is primarily informed by the positive results of a proof-of-concept, Phase 2a study evaluating the safety, immunogenicity, and efficacy of a single dose of 120µg RSVpreF in a human viral challenge model in healthy adults 18 to 50 years of age

Insilico Medicine and EQRx to jointly advance AI-driven drug discovery
Insilico Medicine and EQRx to jointly advance AI-driven drug discovery

By IPP Bureau - March 24, 2022

The collaboration leverages Insilico's end-to-end AI-driven Pharma.AI platform to discover novel small molecule drug candidates for multiple targets, along with EQRx's innovative business model to accelerate drug development and patient access to novel medicines at affordable prices

Totus Medicines partners with Mila on a mission to treat the untreatable
Totus Medicines partners with Mila on a mission to treat the untreatable

By IPP Bureau - March 24, 2022

Organizations to combine expertise to further develop AI/ML-powered drug design platform, delivering precise, effective, and life-changing medicines at scale

Covovax for teens get DCGI nod
Covovax for teens get DCGI nod

By IPP Bureau - March 23, 2022

It is the fourth vaccine to get the nod for 12 years and older after Biological E’s Corbevax, Bharat Biotech’s Covaxin and Zydus Lifesciences Zy-CoV-D

Latest Stories

Interviews

Packaging